More Questions Than Answers in Trial of GRAIL’s Galleri

The NHS-Galleri trial, the first randomized, controlled trial of the multi-cancer early detection test Galleri, found that the test from GRAIL did not meet its primary endpoint, a reduction in late-stage cancers. Researchers say the result could be a consequence of the trial design, which used a surrogate endpoint rather than cancer-specific mortality, the standard measure.